ROCKVILLE, MD and SHENZHEN, CHINA, March 16, 2023— HighTide Therapeutics Inc. (“HighTide”), today announced that Dr. Liping Liu, founder and CEO of HighTide, was selected for the EY Entrepreneurial Winning Women™ Asia-Pacific Class of 2023.

ROCKVILLE, MD and SHENZHEN, CHINA, February 6, 2023 — HighTide Therapeutics Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive

ROCKVILLE, MD and SHENZHEN, CHINA, February 01, 2023 — HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases,

ROCKVILLE, MD and SHENZHEN, CHINA, February 01, 2023 — HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases,

ROCKVILLE, MD and SHENZHEN, CHINA, January 11, 2023 — HighTide Therapeutics Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases,

ROCKVILLE, MD and SHENZHEN, CHINA,January 5, 2023— HighTide Therapeutics Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases,